Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 510

1.

Breast infiltrating ductal carcinoma: analysis of hormone, HER-2 receptors and Ki-67 proliferation marker.

Mustać E, Zamolo G, Petković M, Dordević G, Radić J, Grgurević E, Batinac T.

Coll Antropol. 2008 Sep;32(3):741-6.

PMID:
18982746
2.

Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma.

Ariga R, Zarif A, Korasick J, Reddy V, Siziopikou K, Gattuso P.

Breast J. 2005 Jul-Aug;11(4):278-80.

PMID:
15982396
3.

Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.

Hussein MR, Abd-Elwahed SR, Abdulwahed AR.

Cell Biol Int. 2008 Jun;32(6):698-707. doi: 10.1016/j.cellbi.2008.01.007. Epub 2008 Jan 25.

PMID:
18296077
4.

Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.

Sharif MA, Mamoon N, Mushtaq S, Khadim MT.

J Coll Physicians Surg Pak. 2009 Feb;19(2):99-103. doi: 02.2009/JCPSP.99103.

PMID:
19208313
5.

Multicentric mammary carcinoma: evidence of monoclonal proliferation.

Middleton LP, Vlastos G, Mirza NQ, Eva S, Sahin AA.

Cancer. 2002 Apr 1;94(7):1910-6.

6.

Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.

Bandić D, Juretić A, Sarcević B, Separović V, Kujundzić-Tiljak M, Hudolin T, Spagnoli GC, Cović D, Samija M.

Croat Med J. 2006 Feb;47(1):32-41.

7.

Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.

Papantoniou V, Sotiropoulou E, Valsamaki P, Tsaroucha A, Sotiropoulou M, Ptohis N, Stipsanelli A, Dimitrakakis K, Marinopoulos S, Tsiouris S, Antsaklis A.

Breast Cancer. 2011 Oct;18(4):286-91. doi: 10.1007/s12282-009-0192-y. Epub 2010 Feb 9.

PMID:
20143189
8.

Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases.

Yang M, Moriya T, Oguma M, De La Cruz C, Endoh M, Ishida T, Hirakawa H, Orita Y, Ohuchi N, Sasano H.

Pathol Int. 2003 Jul;53(7):422-8.

PMID:
12828606
9.

Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.

Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Christiaens MR, Vergote I.

Breast Cancer Res Treat. 2005 May;91(1):81-7.

PMID:
15868434
10.

Prostate-specific antigen value as a marker in breast cancer.

Narita D, Cimpean AM, Anghel A, Raica M.

Neoplasma. 2006;53(2):161-7.

PMID:
16575473
11.

Status of HER-2/neu receptors and Ki-67 in breast cancer of Indian women.

Singhai R, Patil V, Patil A.

Int J Appl Basic Med Res. 2011 Jan;1(1):15-9. doi: 10.4103/2229-516X.81974.

12.

Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features.

Middleton LP, Amin M, Gwyn K, Theriault R, Sahin A.

Cancer. 2003 Sep 1;98(5):1055-60.

13.

Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer.

Ivkovic-Kapicl T, Knezevic-Usaj S, Djilas-Ivanovic D, Panjkovic M.

In Vivo. 2007 Jul-Aug;21(4):673-8. Erratum in: In Vivo. 2007 Sep-Oct;21(5):955. In Vivo. 2007 Nov-Dec;21(6):1172.

14.

[Expression and clinical significance of LRP16 gene in human breast cancer].

Liao DX, Han WD, Zhao YL, Pu YD, Mu YM, Luo CH, Li XH.

Ai Zheng. 2006 Jul;25(7):866-70. Chinese.

PMID:
16831279
15.
16.

Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis.

Vaziri SA, Krumroy LM, Elson P, Budd GT, Darlington G, Myles J, Tubbs RR, Casey G.

Clin Cancer Res. 2001 Jul;7(7):1937-45.

17.

Do we need HER-2/neu testing for all patients with primary breast carcinoma?

Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner T, Roka S, Fitzal F, Kandioler D, Sporn E, Friedl J, Mittlböck M, Jakesz R.

Cancer. 2003 Dec 15;98(12):2547-53.

19.

Breast carcinoma in women 35 years and younger: a pathological study.

Fernandopulle SM, Cher-Siangang P, Tan PH.

Pathology. 2006 Jun;38(3):219-22.

PMID:
16753742
20.

The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population.

Kuo WH, Chang LY, Liu DL, Hwa HL, Lin JJ, Lee PH, Chen CN, Lien HC, Yuan RH, Shun CT, Chang KJ, Hsieh FJ.

Taiwan J Obstet Gynecol. 2007 Jun;46(2):135-45. Erratum in: Taiwan J Obstet Gynecol. 2007 Sep;46(3):320-1.

Supplemental Content

Support Center